# MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)

> **NCT01152255** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 18 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** MK6186
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT01152255
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10-10
- **Primary completion:** 2011-06-30
- **Final completion:** 2011-06-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01152255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01152255, "MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01152255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*